Association between gut microbiome, inflammation and statin therapy
2020
KU Leuven, Leuven, Belgium(1)
Sorbonne Université, Paris, France(2)
Sorbonne Université, Paris, France(2)
By exploring obesity-associated microbiota alterations in the quantitative faecal metagenomes of a cross-sectional cohort (n = 888), the authors identify statin therapy as a key covariate of microbiome diversification. Within the subcohort of participants that are not medicated with statins, the prevalence of Bacteroides2 (Bact2) enterotype correlates with body mass index, increasing from 3.90% in lean or overweight participants to 17.73% in obese participants. Systemic inflammation levels in Bact2-enterotyped individuals are higher than predicted on the basis of their obesity status, indicative of Bact2 as a dysbiotic microbiome constellation. Obesity-associated microbiota dysbiosis is negatively associated with statin treatment.
Statin therapy is associated with lower prevalence of gut microbiota dysbiosis
Jeroen Raes(1), Karine Clément(2)
Added on: 07-22-2020
[1] https://www.nature.com/articles/s41586-020-2269-x#Sec2
